SCHEMBL92374

SCHEMBL92374

Cc1cc(F)c(NC(=O)c2c[nH]c3ccccc23)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.61
CFTR P13569 7/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
STING1 Q86WV6 1/20 0.53
NR4A2 P43354 1/20 0.48
CREBBP Q92793 1/20 0.48
PBRM1 Q86U86 1/20 0.48
IGF1R P08069 1/20 0.47
SRC P12931 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADRB3 P13945 1/20 0.47
TBXA2R P21731 1/20 0.47
SLC6A2 P23975 1/20 0.47
AGTR1 P30556 1/20 0.47
MC4R P32245 1/20 0.47
PTGS2 P35354 1/20 0.47
SLC6A3 Q01959 1/20 0.47
GPR84 Q9NQS5 1/20 0.47
NHERF1 O14745 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92571 0.89 NPC1 (0.57) NPC1CFTRMEN1KMT2ASTING1
SCHEMBL92355 0.87 KMT2A (0.67) NPC1CFTRMEN1KMT2ASTING1
SCHEMBL23837127 0.82 CFTR (0.76) CFTRADORA3ADRB3TBXA2RSLC6A2
SCHEMBL20567514 0.81 NPC1 (0.65) NPC1CFTRMEN1KMT2ANR4A2
SCHEMBL31010176 0.81 NPC1 (0.65) NPC1CFTRMEN1KMT2ANR4A2
SCHEMBL28569094 0.81 NR4A2 (0.63) NPC1CFTRMEN1KMT2ANR4A2
SCHEMBL92386 0.80 NPC1 (0.64) NPC1CFTRMEN1KMT2ANR4A2
SCHEMBL92237 0.78 KMT2A (0.64) NPC1MEN1KMT2ARAB9A
SCHEMBL27075304 0.78 NPC1 (0.68) NPC1CFTRMEN1KMT2ASTING1
SCHEMBL92574 0.78 NPC1 (0.61) NPC1CFTRMEN1KMT2ASTING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 NPC1 680/4885CFTR 1242/4885MEN1 4254/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 NPC1 551/4885CFTR 1264/4885MEN1 4337/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 NPC1 624/4885CFTR 1667/4885MEN1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.